Clinical & Investigative Medicine (CIM) is receiving an increasing number of reports of candidate-based association studies. The track record of such studies in the past has been poor: numerous genetic associations reported from candidate gene studies have not been replicated in later studies. The rise of the genome-wide association study (GWAS) is changing this situation. A well-designed GWAS may identify a number of candidate loci without bias by screening the whole human genome. Validating and fine-mapping the candidate loci from GWAS are required to clarify the genetic mechanisms. Thus, a candidate-based association study has become a well-directed effort, instead of searching for a needle in a haystack. In the post-GWAS era, exponential growth of candidate-based genetic association studies is expected. A pressing issue accompanying this new trend is the assessment of the validity of an association study. In this editorial, we illustrate the major cause of false positive association from random sampling bias by an empirical example, and emphasize the application of the probability theory in assessing the validity of a genetic association study.